LR Health & Beauty reported its financial results for 2024. Sales increased to $327.9 million in 2024, representing a year-over-year boost of 4.6%. This increase was driven primarily by the realignment of the career plan and successful launches of the company’s cosmetics line and intestinal metabolism treatment.
EBITDA was $30.9 million, which the company said was “burdened by one-off extraordinary effects,” which included the realignment of the career plan in the fourth quarter and early refinancing of the bond in spring 2024.
“In 2024, we consistently executed our strategy and took a major step toward long-term corporate success with the realignment of our career plan,” said Dr Andreas Laabs, LR Health & Beauty SE CEO. “This year, we are again seeing a strong increase in the number of new distributors who are using our onboarding programs to launch their careers. By continuing to digitalize our business processes, we are empowering our partner community to grow their careers successfully. At the same time, we are expanding our digital offering – whether through training, information, or sales initiatives.”
The company emphasized a positive outlook for 2025, including stable to moderately rising sales revenue and a significant year-over-year increase in EBITDA.
